MTM(SH:688029) SINOLINK SECURITIES·2026-03-01 00:45Investment Rating - The report maintains a "Buy" rating for the company, with expected price-to-earnings (PE) ratios of 27, 21, and 17 for the years 2025, 2026, and 2027 respectively [4] Core Insights - The company is projected to achieve a revenue of 3.191 billion RMB in 2025, representing a year-on-year growth of 16%. The net profit attributable to the parent company is expected to be 570 million RMB, a 3% increase year-on-year [2] - The company's revenue growth is driven by overseas business and new product launches, while domestic operations remain stable. However, profit growth is under pressure due to external factors, including price reductions from centralized procurement and increased costs from foreign exchange fluctuations [2][3] - The establishment of a manufacturing center in Thailand is expected to enhance the company's overseas supply chain and risk resilience, facilitating a one-stop solution for medical consumables [3] Financial Projections - The projected net profits for the company from 2025 to 2027 are 570 million RMB, 723 million RMB, and 897 million RMB, reflecting growth rates of 3%, 27%, and 24% respectively [4] - Revenue is expected to grow from 2.411 billion RMB in 2023 to 4.604 billion RMB in 2027, with a compound annual growth rate (CAGR) of approximately 20.87% [9] - The company’s diluted earnings per share (EPS) is forecasted to increase from 2.587 RMB in 2023 to 4.774 RMB in 2027 [9]